Pfizer (PFE) could use its connections within President Donald Trump’s administration to try to best Novo Nordisk’s (NVO) rival bid to acquire U.S. obesity biotech firm Metsera (MTSR), Reuters’ Michael Erman and Sabrina Valle report. Pfizer has four business days to make a counteroffer, the report notes.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- M&A War: Pfizer Blasts Rival Novo Nordisk for “Reckless” $8.5B Hijack of Metsera Obesity Deal
- Metsera held talks with Bristol Myers before Novo Nordisk, Pfizer, WSJ reports
- Midday Fly By: Big Tech reports, Novo tops Pfizer bid for Metsera
- Metsera receives unsolicted proposal from Novo Nordisk
- Novo Nordisk offers to buy Metsera for up to $77.75 per share, or $9B